The Lynx Group
Cholangiocarcinoma News

Combination Immunotherapy with Ipilimumab and Nivolumab in Patients with Advanced Biliary Tract Cancer

Web Exclusives — May 30, 2020

Combined CTLA-4/PD-1 blockade using ipilimumab and nivolumab has demonstrated superior efficacy compared with single-agent anti–PD-1 therapy in patients with advanced melanoma and renal-cell carcinoma.1 The authors aimed to test this combination in patients with metastatic biliary tract cancer (BTC).2

A total of 39 patients with metastatic BTC were enrolled. Patients received nivolumab 3 mg/kg and ipilimumab 1 mg/kg every 3 weeks for 4 doses, followed by nivolumab 3 mg/kg every 2 weeks. Treatment continued for up to 96 weeks, or until disease progression or the development of unacceptable toxicity. Response was assessed every 12 weeks by RECIST 1.1 criteria. The primary end point was disease control rate (complete response + partial response + stable disease). Exploratory end points included correlation of efficacy with biomarkers, including PD-L1 expression and tumor mutation burden. A total of 33 (85%) patients had received at least 1 prior line of systemic treatment (0-2 lines).

The overall response rate was 24%, the disease control rate was 44%, and the median duration of response was not reached (range, 2-26+ months). Responses were observed in 5 of 16 intrahepatic, 0 of 10 extrahepatic, and 4 of 13 gallbladder cancer patients. None of the responding patients demonstrated tumors with microsatellite instability. Two patients with durable partial responses were subsequently rendered surgically free of disease. Median overall survival and progression-free survival were 5.7 and 2.9 months, respectively. Twenty-two (56%) patients experienced an immune-related adverse event, with grade 3/4 immune-related adverse events being observed in 5 (17%) patients.

The authors concluded that the combination of ipilimumab and nivolumab demonstrated significant clinical activity in patients with microsatellite stable tumors. ClinicalTrials.gov number NCT02923934.

References

  1. Chae YK, et al. J Immunother Cancer. 2018;6(1):39.
  2. Klein O, et al. ASCO 2020. Abstract 4588.

Related Items

Benefits of Lenvatinib plus Pembrolizumab in Solid Tumors, Including Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
First results of the multicohort phase 2 LEAP-005 study suggest that lenvatinib plus pembrolizumab combination immunotherapy has promising antitumor activity in patients with biliary tract cancer.
NTRK Gene Fusions in Biliary Tract Cancers
2020 Year in Review: Cholangiocarcinoma
Molecular analyses of biliary tract cancers indicate that neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare, suggesting that it is not a major driver of BTC pathogenesis.
The Worldwide Incidence of Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
Assessment of global epidemiologic trends in incidence of biliary tract cancers (BTCs) showed higher BTC incidence in Asian versus Western countries as well as intraregional variations within countries, which is consistent with previous reports.
Capecitabine and Cisplatin as Second-Line Chemotherapy for Patients with Advanced Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
Retrospective analysis data suggest that second-line chemotherapy of capecitabine and cisplatin combination therapy was associated with modest efficacy in patients with advanced biliary tract cancer.
Combination Immunotherapy with Ipilimumab and Nivolumab Shows Activity in Patients with Advanced Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
Preliminary data suggest that dual blockade with ipilimumab and nivolumab might have antitumor activity in a subset of patients with microsatellite-stable biliary tract cancer.
Nivolumab with Chemotherapy or Ipilimumab: First-Line Therapy for Patients with Advanced Unresectable Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
Phase 2 study results suggest that the addition of nivolumab and ipilimumab to chemotherapy as first-line therapy did not provide additional PFS benefit compared to standard-of-care chemotherapy in patients with advanced biliary tract cancer.
Phase 2 Study of Nivolumab with Gemcitabine/Cisplatin or Ipilimumab as First-Line Therapy for Patients with Advanced Unresectable BTC (BilT-01)
Web Exclusives
The combinations of nivolumab with gemcitabine/cisplatin or nivolumab with ipilimumab were tested in patients with untreated advanced biliary tract cancer.
Phase 2 Study Assessing Tolerability, Efficacy, and Biomarkers for Durvalumab ± Tremelimumab and Gemcitabine/Cisplatin in Chemo-Naïve Advanced BTC
Web Exclusives
Durvalumab ± tremelimumab plus chemotherapy was well-tolerated and showed promising efficacy in chemotherapy-naïve patients with advanced biliary tract cancer.
Phase 2 Study of mFOLFOX versus mFOLFIRI in Locally Advanced or Metastatic BTC Refractory to First-Line Chemotherapy
Web Exclusives
This randomized phase 2 study showed that mFOLFIRI was not superior to mFOLFOX as second-line treatment of biliary tract cancer.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: